Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations

Clinical Pharmacokinetics

Volumn 49, Issue 3, 2010, Pages 177-188

  Franco Salinas, Gabriela ^a   De La Rosette, Jean J M C H ^b   Michel, Martin C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALPHA1 GLYCOPROTEIN; AMITRIPTYLINE; CIMETIDINE; COLESTILAN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAPOXETINE; DIAZEPAM; DIGOXIN; KETOCONAZOLE; PAROXETINE; PLACEBO; PROPRANOLOL; TAMSULOSIN; THEOPHYLLINE; UDENAFIL; WARFARIN;

AGING; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; FOOD INTAKE; HUMAN; ISOTOPE LABELING; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOWER URINARY TRACT SYMPTOM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEX DIFFERENCE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; LIVER DISEASES; MALE; RENAL INSUFFICIENCY; SEX FACTORS; SULFONAMIDES;

EID: 77249148434     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317580-000000000-00000     Document Type: Review

References (67)

1. 1- adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 2008; 27: 226-230
2. McConnell JD, Roehrborn CG, Bautista O, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl J Med 2003; 349: 2387-2398
3. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-1035
4. 1- adrenoceptors: consensus update. Pharmacol Rev 1995; 47: 267-270
5. 1- adrenoceptor sub-types. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 1-10
6. 2-and b-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147: S88-119
7. Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 1997; 280: 1-5
8. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16: 21-28
9. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008; 62: 1547-1559
10. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319-356
11. 1-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-2343
12. van Dijk MM, de la Rosette JJMCH, Michel MC. Tamsulosin-modified-re-lease and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy 2006; 3: 237-246
13. 1 adrenoceptor antagonist: second report. A single oral dose of controlled release formulation in healthy male subjects. Rinsho Iyaku 1990; 6: 2529-2551
14. 1 adrenoceptor antagonist: third report. Multiple oral doses of controlled release formulation in healthy male subjects. Rinsho Iyaku 1991; 7: 63-93
15. R). European Urology Supplements 2005; 4 (2): 15-24 (Pubitemid 40125734)
16. 1-adrenoceptor antagonism of tamsulosin oral controlled absorption system (OCAS) and modified release (MR) formulations. European Urology Supplements 2005; 4 (2): 45-52 (Pubitemid 40125736)
17. Michel MC, Korstanje C, Krauwinkel W, et al. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. European Urology Supplements 2005; 4 (2): 53-60 (Pubitemid 40125737)
18. 1 adrenoceptor antagonist: first report. A single oral dose of conventional formulation in healthy male subjects. Rinsho Iyaku 1990; 6: 2503-2528
19. Matsushima H, Kamimura H, Soeishi Y, et al. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs and humans. Drug Metab Dispos 1998; 26: 240-245
20. Yokoyama O, Takada A, Matsuhima H, et al. Bioequivalence study for tam-sulosin hydrochloride 0.2mg oral disintegrating tablets (WOWTAB) and 0.2 mg capsules in humans under the fed condition. Jpn Pharmacol Ther 2005; 33: 521-526 (Pubitemid 41261870)
21. Yokoyama O, Takada A, Matsushima H, et al. Bioequivalence study for tamsulosin hydrochloride 0.2mg oral disintegrating tablets (WOWTAB) and 0.2mg capsules in humans under the fasted condition. Jpn Pharmacol Ther 2005; 33: 527-533 (Pubitemid 41261871)
22. Yokoyama O, Takada A, Matsushima H, et al. Bioequivalence study for tamsulosin hydrochloride 0.2mg and 0.1 mg oral disintegrating tablets (WOWTAB) in humans. Jpn Pharmacol Ther 2005; 33: 535-540
23. Elias-Al-Mamun M, Khan HA, Dewan I, et al. In vitro study on tamsulosin release kinetics from biodegradable PLGA in situ implants. Pak J Pharm Sci 2009; 22: 360-367
24. 1-acid glycoprotein and possibility of binding interactions. Eur J Clin Pharmacol 1999; 55: 437-443
25. Soeishi Y, Kobori M, Kobayashi S, et al. Sensitive method for the determina-tion of amsulosin in human plasma using high-performance liquid chromatography with fluorescence detection. J Chromatography B 1990; 533: 291-296
26. Ding L, Li L, Tao P, et al. Quantitation of tamsulosin in human plasma by liquid chromatography-electroscopy ionization mass spectrometry. J Chromatography B 2002; 767: 75-81
27. Qi M, Wang P, Liu L. Determination of tamsulosin in dog plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatography B 2004; 805: 7-11
28. 14C-amsulosin hydrochloride in rats and dogs. Pharmacometrics 1990; 40: 101-109
29. 1-adrenoceptor antagonists. J Pharmacol Exp Ther 2002; 300: 495-504
30. 1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997; 86: 1156-1161
31. Taguchi K, Schafers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 1998; 45: 49-55
32. Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res 2001; 62: 603-621
33. Miyazawa Y, Forrest A, Schentag JJ, et al. Effect of concomitant adminis-tration of cimetidine hydrochloride on the pharmacokinetic and safety profile of tamsulosin hydrochloride 0.4 mg in healthy subjects. Curr Ther Res 2002; 63: 15-26
34. Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998; 54: 367-373
35. Michel MC, Chapple CR. Comparison of the cardiovascular effects of tam-sulosin oral controlled absorption system (OCAS®) and alfuzosin prolonged release (XL). Eur Urol 2006; 49: 501-509
36. Stevens HNE, Speakman M. Behaviour and transit of tamsulosin oral controlled absorption system in the gastrointestinal tract. Curr Med Res Opin 2006; 22: 2323-2328
37. Flomax® (tamsulosin hydrochloride capsules): US prescribing information. Deerfield (IL): Astellas Pharma US, Inc., 2009 Dec [online]. Available from: http:/ /bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet. ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Flomax+Caps/ Flomax.pdf [Accessed 2009 Dec 14]
38. Djavan B, Milani S, Davies J, et al. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. European Urology Supplements 2005; 4 (2): 61-68
39. 1 adrenoceptors in rat tissues in relation to the pharmacokinetics. J Pharmacol Exp Ther 1999; 289: 1575-1583
40. Sato S, Ohtake A, Matsushima H, et al. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther 2001; 296: 697-703
41. Romic I, Kiss T, Kisbenedek L, et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol 2003; 169 Suppl.: 288
42. 1-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J Pharm Sci 2000; 89: 490-498
43. 1-acid glycoprotein. J Clin Pharmacol 1996; 36: 1029-1038
44. Soeishi Y, Matsushima H, Teraya Y, et al. Metabolism of tamsulosin in the rat and dog. Xenobiotica 1996; 26: 355-365
45. Soeishi Y, Matsushima H, Watanabe T, et al. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 1996; 26: 637-645
46. 1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998; 28: 909-922
47. Robinson D, Cardozo L, Terpstra G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007; 100: 840-845
48. Michel MC, de la Rosette JJMCH. a-Blocker treatment of urolithiasis. Eur Urol 2006; 50: 213-214
49. Michel MC, Mehlburger L, Bressel H-U, et al. Tamsulosin treatment of 19 365 patients with lower urinary tract symptoms: does comorbidity alter toler-ability? J Urol 1998; 160: 784-791
50. Miyazawa Y, Starkey LP, Forrest A, et al. Effects of concomitant adminis-tration of tamsulosin (0.8mg/day) on the pharmacokinetic and safety profile of theophylline (5mg/kg): a placebo-controlled evaluation. J Int Med Res 2002; 30: 34-43
51. Rolan P, Clarke C, Mullins F, et al. Assessment of potential effects of tam-sulosin (Omnic®) on the pharmacokinetics and pharmacodynamics of nicoumalone: are there interactions between tamsulosin (Omnis®) and nicoumalone? [abstract]. J Urol 1999; 161 Suppl.: 235
52. Rolan P, Terpstra IJ, Clarke C, et al. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocou-marol. Br J Clin Pharmacol 2003; 55: 314-316
53. Kang HE, Bae SK, Yoo M, et al. Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2. Br J Pharmacol 2009; 156: 1009-1018
54. Miyazawa Y, Starkey LP, Forrest A, et al. Effects of concomitant adminis-tration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects: a placebo-controlled evaluation. J Clin Pharm Ther 2002; 27: 13-19 (Pubitemid 34175431)
55. Suzuki K, Kawai M, Kaneko N, et al. Study of interactions among colestimide and drugs (2nd report): comparison with cholestyramine. Jpn Pharmacol Ther 2001; 29: 37-44
56. Troost J, Tatami S, Tsuda Y, et al. Effects of the CYP3A4 inhibitor ketoco-nazole on the pharmacokinetics of a single oral dose of tamsulosin. Br J Clin Pharmacol. In press
57. Troost J, Tatami S, Tsuda Y, et al. Effects of the CYP2D6 inhibitor paroxetine on the pharmacokinetics of a single oral dose of tamsulosin. Br J Clin Pharmacol. In press
58. Modi NB, Kell S, Aquilina J, et al. Effect of dapoxetine on the pharmaco-kinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. J Clin Pharmacol 2008; 48: 1438-1450
59. 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 587-596
60. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in be-nign prostatic hyperplasia. Urology 1998; 51: 892-900
61. Narayan P, Tewari A, Members of United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-1706
62. Chapple CR, Al-Shukri SH, Gattegno B, et al. Tamsulosin oral controlled absorp-tion system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. European Urology Supplements 2005; 4 (2): 33-44
63. Michel MC, Korstanje C, Krauwinkel W. Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. European Urology Supplements 2005; 4 (2): 9-14
64. Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and toler-ability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-1088 (Pubitemid 39647042)
65. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730-742
66. Michel MC, Bressel H-U, Goepel M, et al. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 2001; 51: 609-614
67. Michel MC, Neumann HG, Mehlburger L, et al. Does time of administration (morning vs evening) affect the tolerability or efficacy of tamsulosin? BJU Int 2001; 87: 31-34